DrugDashboards

Creon

Pancrelipase · PANCRELIPASE AMYLASE 15000 [USP'U]/1; PANCRELIPASE LIPASE 3000 [USP'U]/1; PANCRELIPASE PROTEASE 9500 [USP'U]/1 · Capsule, Delayed Release · Oral · AbbVie Inc.

NDC 00032-0045-30 · 70 CAPSULE, DELAYED RELEASE in 1 BOTTLE · BLA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 00032-1203-70) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$1.79per unit
middle half $1.76–$1.87 · 5,347 plans · Apr 1, 2026
Est. net of rebatesⓘ
$1.07–$1.34
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
97%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for pancrelipase (oral solid) in the next 90 days

sole-source market · price up 2% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 2 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $1,926.88 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
BLA020725
TE code
—
Approval date
—
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · TerminatedMar 15, 2021
    Cardinal Health Inc. — CGMP Deviations: Intermittent exposure to temperature excursion during storage.
  • Class II · TerminatedSep 15, 2014
    AbbVie Inc — Presence of Foreign Tablets/Capsules; Presence of co-mingled LipaCreon 13000.

Manufacturers of Pancrelipase (Capsule, Delayed Release)

LabelerStrengthFirst seenLast seen
AbbVie Inc.PANCRELIPASE AMYLASE 15000 [USP'U]/1; PANCRELIPASE LIPASE 3000 [USP'U]/1; PANCRELIPASE PROTEASE 9500 [USP'U]/1Jul 15, 2026Sep 3, 2026
Digestive Care, Inc.PANCRELIPASE LIPASE 16000 [USP'U]/1; PANCRELIPASE AMYLASE 60500 [USP'U]/1; PANCRELIPASE PROTEASE 57500 [USP'U]/1Aug 26, 2026Sep 2, 2026
Digestive Care, Inc.PANCRELIPASE LIPASE 24000 [USP'U]/1; PANCRELIPASE AMYLASE 90750 [USP'U]/1; PANCRELIPASE PROTEASE 86250 [USP'U]/1Aug 26, 2026Sep 2, 2026
Digestive Care, Inc.PANCRELIPASE LIPASE 4000 [USP'U]/1; PANCRELIPASE AMYLASE 15125 [USP'U]/1; PANCRELIPASE PROTEASE 14375 [USP'U]/1Aug 26, 2026Sep 2, 2026
Digestive Care, Inc.PANCRELIPASE LIPASE 8000 [USP'U]/1; PANCRELIPASE AMYLASE 30250 [USP'U]/1; PANCRELIPASE PROTEASE 28750 [USP'U]/1Aug 26, 2026Sep 2, 2026
Digestive Care, Inc.PANCRELIPASE LIPASE 15125 [USP'U]/1; PANCRELIPASE AMYLASE 4000 [USP'U]/1; PANCRELIPASE PROTEASE 14375 [USP'U]/1Jul 22, 2026Aug 19, 2026
Digestive Care, Inc.PANCRELIPASE LIPASE 60500 [USP'U]/1; PANCRELIPASE AMYLASE 16000 [USP'U]/1; PANCRELIPASE PROTEASE 57500 [USP'U]/1Jul 22, 2026Aug 19, 2026
Digestive Care, Inc.PANCRELIPASE LIPASE 30250 [USP'U]/1; PANCRELIPASE AMYLASE 8000 [USP'U]/1; PANCRELIPASE PROTEASE 28750 [USP'U]/1Jul 22, 2026Aug 19, 2026
Digestive Care, Inc.PANCRELIPASE LIPASE 90750 [USP'U]/1; PANCRELIPASE AMYLASE 24000 [USP'U]/1; PANCRELIPASE PROTEASE 86250 [USP'U]/1Jul 22, 2026Aug 19, 2026
Digestive Care, Inc.PANCRELIPASE AMYLASE 90750 [USP'U]/1; PANCRELIPASE LIPASE 24000 [USP'U]/1; PANCRELIPASE PROTEASE 86250 [USP'U]/1Jul 15, 2026Jul 15, 2026
Digestive Care, Inc.PANCRELIPASE AMYLASE 15125 [USP'U]/1; PANCRELIPASE LIPASE 4000 [USP'U]/1; PANCRELIPASE PROTEASE 14375 [USP'U]/1Jul 15, 2026Jul 15, 2026
Digestive Care, Inc.PANCRELIPASE AMYLASE 30250 [USP'U]/1; PANCRELIPASE LIPASE 8000 [USP'U]/1; PANCRELIPASE PROTEASE 28750 [USP'U]/1Jul 15, 2026Jul 15, 2026
Digestive Care, Inc.PANCRELIPASE AMYLASE 60500 [USP'U]/1; PANCRELIPASE LIPASE 16000 [USP'U]/1; PANCRELIPASE PROTEASE 57500 [USP'U]/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Creon — NDC 00032-0045-30," retrieved September 3, 2026, https://drugdashboards.com/drug/00032004530.

Free to cite with attribution — see how the data is put together.